617 A Phase I study of a tumor-targeted, fibroblast activation protein (FAP)-CD40 agonist (RO7300490) in patients with advanced solid tumors

• Antoine Hollebecque,
• Victor Moreno,
• Do-Youn Oh,
• Ignacio Melero,
• James Spicer,
• Iben Spanggaard,
• Fiona C Thistlethwaite,
• Stefan Symeonides,
• Maria Lostes Baradji,
• Dae Lee,
• Corinne Rusterholz,
• Olivera Cirovic,
• Yvonne Zhao,
• Nicole Kratochwil,
• Bernhard Reis,
• Alexandra Epp,
• Georgios Kazantzidis

Affiliations

Antoine Hollebecque

9Gustave Roussy, Villejuif, France

Victor Moreno

11 Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain

Do-Youn Oh

Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea

Ignacio Melero

17 Clinica Universidad de Navarra-Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain

James Spicer

School of Cancer & Pharmaceutical Sciences, King`s College London, London, UK

Iben Spanggaard

3Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark

Fiona C Thistlethwaite

4The Christie, NHS Foundation Trust, Manchester, UK and University of Manchester, Manchester, UK

Stefan Symeonides

1Edinburgh Cancer Research Centre, University of Edinburgh, and Edinburgh Cancer Centre, NHS Lothian, Edinburgh, UK

Maria Lostes Baradji

2Vall d’Hebron Institute of Oncology, Barcelona, Spain

Dae Lee

4University of Ulsan College of Medicine, Seoul, Republic of Korea

Corinne Rusterholz

10Roche Pharma Research and Early Development, Early Clinical Development, Roche Innovation Center Basel, Basel, Switzerland

Olivera Cirovic

11Roche Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland

Yvonne Zhao

12Roche Product Development Safety, Roche (China) Holding Ltd, Shanghai, China

Nicole Kratochwil

13Roche Pharma Research and Early Development, Pharmaceutical Science, Basel, Switzerland

Bernhard Reis

11Roche Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland

Alexandra Epp

14Roche Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Munich, Munich, Germany

Georgios Kazantzidis

15Roche Data Science and Statistics, Biostatistics Oncology, Basel, Switzerland